This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-02. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
==== Lists of nidanas ==== In the early Buddhist texts, dependent origination is analyzed and expressed in various lists of dependently originated phenomena (dhammas) or causes (nidānas). Nidānas are co-dependent principles, processes or events, which act as links on a chain, conditioning and depending on each other. When certain conditions are present, they give rise to subsequent conditions, which in turn give rise to other conditions. Phenomena are sustained only so long as their sustaining factors remain. The most common one is a list of twelve causes (Pali: dvādasanidānāni, Sanskrit: dvādaśanidānāni). Bucknell refers to it as the "standard list". It is found in section 12 of the Samyutta Nikaya and its parallels, as well as in other suttas belonging to other Nikayas and Agamas. This list also appears in Mahasamghika texts like the Salistamba Sutra and in (later) works like Abhidharma texts and Mahayana sutras. According to Eviatar Shulman, "the 12 links are paticcasamuppada," which is a process of mental conditioning. Cox notes that even though the early scriptures contain numerous variations of lists, the 12 factor list became the standard list in the later Abhidharma and Mahayana treatises. The most common interpretation of the twelve cause list in the traditional exegetical literature is that the list is describing the conditional arising of rebirth in saṃsāra, and the resultant duḥkha (suffering, pain, unsatisfactoriness).
Overall, there are various non-selective calcium channel blockers that help alleviate symptoms of hypertension, schizophrenia, cardiac arrhythmia, epilepsy, pain, asthma, bradycardia, angina pectoris and Alzheimer's disease. Although many of the therapeutic compounds' main target is not P-type channels, further research needs to determine if the clinical effects of these compounds are also influenced by the P-type channel blockage.
== Methods == Prohibited methods include manipulation of blood components (e.g. autologous red blood cell transfer, "blood doping"), manipulation of samples, and gene doping. These are prohibited at all times.
People with hyperthyroidism absorb much more iodine than healthy people, including radioactive iodine, which is easy to measure. A thyroid scan producing images is typically conducted in connection with the uptake test to allow visual examination of the over-functioning gland. Thyroid scintigraphy is a useful test to characterize (distinguish between causes of) hyperthyroidism, and this entity from thyroiditis. This test procedure typically involves two tests performed in connection with each other: an iodine uptake test and a scan (imaging) with a gamma camera. The uptake test involves administering a dose of radioactive iodine (radioiodine), traditionally iodine-131 (131I), and more recently iodine-123 (123I). Iodine-123 may be the preferred radionuclide in some clinics due to its more favorable radiation dosimetry (i.e., less radiation dose to the person per unit administered radioactivity) and a gamma photon energy more amenable to imaging with the gamma camera. For the imaging scan, I-123 is considered an almost ideal isotope of iodine for imaging thyroid tissue and thyroid cancer metastasis. Thyroid scintigraphy should not be performed in those who are pregnant, a thyroid ultrasound with color flow doppler may be obtained as an alternative in these circumstances. Typical administration involves a pill or liquid containing sodium iodide (NaI) taken orally, which contains a small amount of iodine-131, amounting to perhaps less than a grain of salt. A 2-hour fast of no food before and for 1 hour after ingesting the pill is required.
Sources: en.wikipedia.org
== Cause == Beriberi is often caused by eating a diet with a very high proportion of calorie-rich white rice (common in Asia) or cassava root (common in sub-Saharan Africa), without much if any thiamine-containing animal products or vegetables. It may also be caused by shortcomings other than inadequate intake – diseases or operations on the digestive tract, alcoholism, dialysis or genetic deficiencies. All those causes mainly affect the central nervous system, and provoke the development of Wernicke's encephalopathy. Wernicke's disease is one of the most prevalent neurological or neuropsychiatric diseases. In autopsy series, features of Wernicke lesions are observed in approximately 2% of general cases. Medical record research shows that about 85% had not been diagnosed, although only 19% would be asymptomatic. In children, only 58% were diagnosed. In alcohol abusers, autopsy series showed neurological damages at rates of 12.5% or more. Mortality caused by Wernicke's disease reaches 17% of diseases, which means 3.4/1000 or about 25 million contemporaries. The number of people with Wernicke's disease may be even higher, considering that early stages may have dysfunctions prior to the production of observable lesions at necropsy. In addition, uncounted numbers of people can experience fetal damage and subsequent diseases.
Zvi Mowshowitz (2001), founder of MetaMed and former Magic: The Gathering world champion Daryl Ng (2001), executive director of Sino Group, son of Singaporean real estate billionaire Robert Ng Courtney Reum (2001), investor who founded VeeV spirits Adriana Cisneros (2002), vice chairman and CEO of Grupo Cisneros; daughter of Venezuelan media mogul Gustavo Cisneros Ellen Gustafson (2002), businesswoman, social entrepreneur, food activist, co-founder of FEED Projects and former spokesperson for the World Food Programme Peter Koechley (2003), co-founder of Upworthy and former managing editor of The Onion Aaron Bay-Schuck (2003), CEO and co-chairman of Warner Records, stepson of Star Trek actor Leonard Nimoy Carter Reum (2003), author and entrepreneur, founder of VEEV Spirits and known for his romance with socialite Paris Hilton Anna Fang (2004), Chinese investor, CEO of ZhenFund Jamie Hodari (2004), co-founder of Industrious Alicia Yoon (2004), founder of Peach and Lily, a Korean skincare store based in New York Doug Imbruce (2005), founder of Qwiki and Podz John Kluge Jr.
The Green Book, formally titled Quantities, Units and Symbols in Physical Chemistry, is a compilation of terms and symbols widely used in the field of physical chemistry. It also includes a table of physical constants, tables listing the properties of elementary particles, chemical elements, and nuclides, and information about conversion factors that are commonly used in physical chemistry. The most recent is the third edition (ISBN 978-0-85404-433-7), originally published by IUPAC in 2007. A second printing of the third edition was released in 2008; this printing made several minor revisions to the 2007 text. A third printing of the third edition was released in 2011. The text of the third printing is identical to that of the second printing.
Sources: en.wikipedia.org
== Ethanol as a replacement for dry gas == Most gasoline now contains approximately 10–15% ethanol solution. Current gasoline-powered automobiles can safely run with up to a 10% ethanol solution without requiring any modification. However, when the ethanol content reaches 15% or higher, older vehicles need to replace their fuel lines to prevent degradation and rupture. In this case, the electric fuel pump may also need modification to prevent ethanol "dry rot". It is mostly true that dry gas is no longer needed due to the ethanol added to modern fuels, as ethanol is a drying agent that has an affinity for water present in the atmosphere. It binds to the fuel tank's moisture, reducing freezing in fuel lines. Adding dry gas lowers the freezing point of the water and alcohol mixture further than what the ethanol in fuel can produce, causing fuel lines to become more freeze resistant.
It was not until the beginning of the 17th century, when Grotius and his successors developed the idea of international law, that the balance of power was formulated as a fundamental principle of diplomacy, although this formulation must have reflected existing practices. In accordance with this new discipline, the European states formed a sort of federal community, the fundamental condition of which was the preservation of a balance of power, i.e., such a disposition of things that no one state, or potentate, should be able absolutely to predominate and prescribe laws to the rest. And, since all were equally interested in this settlement, it was held to be the interest, the right, and the duty of every power to interfere, even by force of arms, when any of the conditions of this settlement were infringed upon, or assailed by, any other member of the community.
The three substrates of this enzyme are taxusin, oxygen, and a proton. It uses a reduced nicotinamide adenine dinucleotide (NADH) cofactor bound to a heme in cytochrome P450 to give 7β-hydroxytaxusin and water as products. The enzyme is found in the yew tree Taxus cuspidata and is part of the pathway for the biosynthesis of taxol.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.